After the initial boom between 2017 and 2019, Canada’s cannabis sector has largely remained in a downturn. However, strategic shifts by certain leading companies are now highlighting potential value for long-term investors. Two stocks in particular—Curaleaf and Cronos Group—are drawing attention due to improved profitability and distinct market positioning.
Curaleaf (TSX: CURA), one of the largest U.S. multi-state cannabis operators listed in Canada, stands out with its extensive retail network across multiple states and consistent revenue growth. While many Canadian cannabis companies continue to face profitability challenges, analysts project that Curaleaf could achieve profitability within the next two years—a rare expectation in the sector.
As the trend toward cannabis legalization gains momentum in the U.S., Curaleaf’s expanding retail presence in key markets makes it a compelling choice for investors looking to capitalize on long-term industry recovery. For those optimistic about U.S. market potential and regulatory progress, this stock offers a strategic entry point.
Although Cronos Group (TSX: CRON), a player focused on the Canadian market, saw its share price drop significantly after the initial hype, it has rebounded by more than 20% over the past year. A major driver behind this recovery is its achievement of profitability, reporting earnings per share of CA$0.15. By building a premium brand and diversifying its product portfolio, Cronos has successfully moved away from competing on low-margin commodities and now caters to consumers seeking higher-quality cannabis.
Against the backdrop of growing demand for premium cannabis in Canada, Cronos has leveraged brand strength and product differentiation to become one of the few domestic players with sustainable competitive potential.
Despite ongoing pessimism in the broader cannabis market, leading companies in both the U.S. and Canada are showing early signs of a turnaround through strategic repositioning. For investors who believe the industry will mature and become consistently profitable, Curaleaf and Cronos offer two distinct pathways: one through cross-market expansion, and the other through premium domestic branding.
That said, the cannabis industry remains sensitive to regulatory changes and market volatility. Investors should maintain a long-term view when considering these stocks.
